Details of the Drug Combination

General Information of Drug Combination (ID: DCD84IT)

Drug Combination Name
Trimethobenzamide Etomidate
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Trimethobenzamide   DMPP4DT Etomidate   DMZI3WO
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 5.37
Bliss Independence Score: 5.37
Loewe Additivity Score: 15.32
LHighest Single Agent (HSA) Score: 15.32

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Trimethobenzamide
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [2]
Nausea and vomiting MD90 Approved [3]
Vomiting MD90 Approved [2]
Indication(s) of Etomidate
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [4]
Etomidate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
GABA(A) receptor gamma-3 (GABRG3) TTEX6LM GBRG3_HUMAN Modulator [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Trimethobenzamide FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5463).
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.